Appropriateness of proton pump inhibitors use in noncritically ill hospitalized children in a tertiary hospital in Saudi Arabia.
Child
Cross-sectional study
Hospitalization
Infant
Omeprazole
Pediatric
Proton pump inhibitor
Journal
Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society
ISSN: 1319-0164
Titre abrégé: Saudi Pharm J
Pays: Saudi Arabia
ID NLM: 9705695
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
03
05
2023
accepted:
24
07
2023
medline:
23
8
2023
pubmed:
23
8
2023
entrez:
23
8
2023
Statut:
ppublish
Résumé
Studies assessing the appropriate use of proton pump inhibitors (PPIs) for hospitalized noncritically ill pediatric patients are lacking. Therefore, this study aimed to assess the suitability of PPI prescriptions in noncritically ill pediatric patients. This cross sectional retrospective study was conducted at a maternity hospital in Qassim, Saudi Arabia from November 2020 to January 2021. All noncritically ill hospitalized children aged 14 years and below who received PPIs were included. The endpoints included the number and percentage of patients who appropriately received PPIs in general and in each age category. The collected data were analyzed using Microsoft Excel (version 2208, Microsoft Corp., Redmond, WA, USA). In total, 332 medical records were screened, of which 246 were included. Of all patients, 49.2% were children and 50.8% were infants, with the average age at admission being 5.39 ± 5.4 years years. More than half of the patients were female, and the average weight of patients was 19.8 kg. Omeprazole was appropriately used in 95 (38.5%) patients. Based on age groups, omeprazole was appropriately used in 66.3% of children and 38.4% of infants. The use of omeprazole in noncritically ill pediatrics was only deemed appropriate in 38.6% of the study population. This result indicates that this medication was overused in the institution. Additional research is required to confirm this on a nationwide scale.
Sections du résumé
Background
UNASSIGNED
Studies assessing the appropriate use of proton pump inhibitors (PPIs) for hospitalized noncritically ill pediatric patients are lacking. Therefore, this study aimed to assess the suitability of PPI prescriptions in noncritically ill pediatric patients.
Methods
UNASSIGNED
This cross sectional retrospective study was conducted at a maternity hospital in Qassim, Saudi Arabia from November 2020 to January 2021. All noncritically ill hospitalized children aged 14 years and below who received PPIs were included. The endpoints included the number and percentage of patients who appropriately received PPIs in general and in each age category. The collected data were analyzed using Microsoft Excel (version 2208, Microsoft Corp., Redmond, WA, USA).
Results
UNASSIGNED
In total, 332 medical records were screened, of which 246 were included. Of all patients, 49.2% were children and 50.8% were infants, with the average age at admission being 5.39 ± 5.4 years years. More than half of the patients were female, and the average weight of patients was 19.8 kg. Omeprazole was appropriately used in 95 (38.5%) patients. Based on age groups, omeprazole was appropriately used in 66.3% of children and 38.4% of infants.
Conclusion
UNASSIGNED
The use of omeprazole in noncritically ill pediatrics was only deemed appropriate in 38.6% of the study population. This result indicates that this medication was overused in the institution. Additional research is required to confirm this on a nationwide scale.
Identifiants
pubmed: 37608963
doi: 10.1016/j.jsps.2023.101723
pii: S1319-0164(23)00218-9
pmc: PMC10440568
doi:
Types de publication
Journal Article
Langues
eng
Pagination
101723Informations de copyright
© 2023 The Authors.
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Best Pract Res Clin Gastroenterol. 2001 Jun;15(3):355-70
pubmed: 11403532
Infect Control Hosp Epidemiol. 2016 Dec;37(12):1408-1417
pubmed: 27677811
Expert Rev Clin Pharmacol. 2013 Jul;6(4):443-51
pubmed: 23927671
Ann Pharmacother. 2015 Sep;49(9):1004-8
pubmed: 26139638
Gut. 2014 Apr;63(4):552-8
pubmed: 23856153
JAMA Intern Med. 2017 Jun 1;177(6):784-791
pubmed: 28346595
Pharmacol Ther. 2003 Apr;98(1):109-27
pubmed: 12667890
J Crit Care. 2014 Aug;29(4):696.e11-5
pubmed: 24674763
Aliment Pharmacol Ther. 2005 May 15;21(10):1203-9
pubmed: 15882240
Paediatr Drugs. 2013 Apr;15(2):119-31
pubmed: 23512128
J Pediatr Gastroenterol Nutr. 2014 Feb;58(2):220-5
pubmed: 24464148
Crit Care Resusc. 2013 Jun;15(2):147-51
pubmed: 23961576
BMJ. 2020 Jan 6;368:l6744
pubmed: 31907166
World J Gastrointest Pharmacol Ther. 2016 Nov 6;7(4):531-539
pubmed: 27867686
Aliment Pharmacol Ther. 2010 Jun;31(11):1165-77
pubmed: 20222914
Pediatr Crit Care Med. 2010 Jan;11(1):124-32
pubmed: 19770788
Saudi J Gastroenterol. 2010 Oct-Dec;16(4):275-9
pubmed: 20871193
Crit Care. 2002 Dec;6(6):526-30
pubmed: 12493075
BMJ Open. 2019 Jul 10;9(7):e024377
pubmed: 31296505
Pharmacotherapy. 1997 Jan-Feb;17(1):22-37
pubmed: 9017763
J Crit Care. 2010 Jun;25(2):214-20
pubmed: 19683892
Pediatrics. 1998 Oct;102(4 Pt 1):933-8
pubmed: 9755268
Pharmacotherapy. 2013 Sep;33(9):956-71
pubmed: 23712734
J Pediatr Gastroenterol Nutr. 2009 Oct;49(4):498-547
pubmed: 19745761
J Eval Clin Pract. 2013 Apr;19(2):374-8
pubmed: 22420909
Clin Pharmacol Ther. 2012 Sep;92(3):388-92
pubmed: 22805424
Int J Clin Pharm. 2015 Dec;37(6):1152-61
pubmed: 26319396
Am J Health Syst Pharm. 1999 Feb 15;56(4):347-79
pubmed: 10690219
Intensive Care Med. 2013 Feb;39(2):165-228
pubmed: 23361625
J Asthma. 2020 Aug;57(8):858-865
pubmed: 31046509
BMC Med. 2016 Nov 9;14(1):179
pubmed: 27825371
BMJ. 2020 Jan 6;368:l6722
pubmed: 31907223
Am J Gastroenterol. 2012 Jul;107(7):1011-9
pubmed: 22525304
J Pediatr Gastroenterol Nutr. 2007 Oct;45(4):421-7
pubmed: 18030207
Dig Dis Sci. 2008 Feb;53(2):385-93
pubmed: 17676398
J Pediatr Gastroenterol Nutr. 2011 Aug;53(2):230-43
pubmed: 21558964
Am J Gastroenterol. 2013 May;108(5):679-92; quiz 693
pubmed: 23567357
Pediatr Crit Care Med. 2020 Feb;21(2):e107-e113
pubmed: 31821206
An Pediatr (Engl Ed). 2022 May;96(5):402-409
pubmed: 35701033
World J Gastrointest Pharmacol Ther. 2012 Dec 6;3(6):93-6
pubmed: 23494814
Rev Esp Enferm Dig. 2015 Nov;107(11):652-8
pubmed: 26541654
J Eval Clin Pract. 2007 Oct;13(5):716-21
pubmed: 17824863
Aliment Pharmacol Ther. 2003 Jun 15;17(12):1503-6
pubmed: 12823152